Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE:002099)
7.53
-0.01 (-0.13%)
Mar 10, 2026, 11:25 AM CST
SHE:002099 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -334.96 | -330.27 | -420.06 | 88.01 | 95.23 | 319.72 | Upgrade
|
| Depreciation & Amortization | 342.54 | 342.54 | 364.6 | 336.52 | 294.23 | 256.57 | Upgrade
|
| Other Amortization | 1.79 | 1.79 | 1.17 | 0.46 | 0.26 | 0.22 | Upgrade
|
| Loss (Gain) From Sale of Assets | -1.04 | -1.04 | -12.88 | -0.29 | 1.48 | -0.34 | Upgrade
|
| Asset Writedown & Restructuring Costs | 242.85 | 242.85 | 132.82 | 60.16 | -0.55 | 0.99 | Upgrade
|
| Loss (Gain) From Sale of Investments | 27.68 | 27.68 | 83.92 | 27.27 | -9.8 | 20.31 | Upgrade
|
| Provision & Write-off of Bad Debts | 4.54 | 4.54 | -13.41 | 17.53 | 10.08 | 2.23 | Upgrade
|
| Other Operating Activities | 34.54 | 152.39 | 171.89 | -36.1 | 61.59 | 76.22 | Upgrade
|
| Change in Accounts Receivable | -340.3 | -340.3 | 2.74 | -229.76 | -754.98 | -353.18 | Upgrade
|
| Change in Inventory | -264.23 | -264.23 | 293.73 | -213.74 | -194.08 | 102.12 | Upgrade
|
| Change in Accounts Payable | 347.63 | 347.63 | -316.52 | 67.64 | 601.96 | 60.28 | Upgrade
|
| Operating Cash Flow | 52.3 | 174.83 | 240.54 | 116.09 | 102.36 | 533.87 | Upgrade
|
| Operating Cash Flow Growth | -60.59% | -27.32% | 107.19% | 13.41% | -80.83% | -12.82% | Upgrade
|
| Capital Expenditures | -98.73 | -122.11 | -153.08 | -179.42 | -229.56 | -74.18 | Upgrade
|
| Sale of Property, Plant & Equipment | 8.08 | 8.09 | 24.34 | 5.66 | 9.23 | 3.72 | Upgrade
|
| Divestitures | -24 | - | - | - | 0.16 | - | Upgrade
|
| Investment in Securities | 24.13 | 24 | -40.5 | -459.13 | -254 | -0.12 | Upgrade
|
| Other Investing Activities | -277.88 | -437.37 | 41.03 | 12.58 | -34.84 | - | Upgrade
|
| Investing Cash Flow | -368.4 | -527.39 | -128.21 | -620.32 | -509.01 | -70.58 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 460 | Upgrade
|
| Long-Term Debt Issued | - | 2,507 | 2,307 | 2,228 | 1,069 | - | Upgrade
|
| Total Debt Issued | 2,289 | 2,507 | 2,307 | 2,228 | 1,069 | 460 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -230 | Upgrade
|
| Long-Term Debt Repaid | - | -2,591 | -2,321 | -1,822 | -934.76 | - | Upgrade
|
| Total Debt Repaid | -2,434 | -2,591 | -2,321 | -1,822 | -934.76 | -230 | Upgrade
|
| Net Debt Issued (Repaid) | -144.63 | -84.56 | -14.51 | 406.11 | 134.24 | 230 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 236.9 | Upgrade
|
| Repurchase of Common Stock | -151.42 | -151.42 | - | - | - | - | Upgrade
|
| Common Dividends Paid | -23.61 | -28.06 | -118.94 | -195.44 | -53.45 | -478.09 | Upgrade
|
| Other Financing Activities | 457.15 | 267.5 | 232.52 | -332.55 | - | - | Upgrade
|
| Financing Cash Flow | 137.49 | 3.46 | 99.07 | -121.88 | 80.79 | -11.19 | Upgrade
|
| Foreign Exchange Rate Adjustments | 16.55 | 35.69 | 1.1 | 75.13 | -25.53 | -38.48 | Upgrade
|
| Net Cash Flow | -162.06 | -313.4 | 212.5 | -550.97 | -351.39 | 413.62 | Upgrade
|
| Free Cash Flow | -46.43 | 52.73 | 87.46 | -63.33 | -127.2 | 459.69 | Upgrade
|
| Free Cash Flow Growth | - | -39.72% | - | - | - | 1.75% | Upgrade
|
| Free Cash Flow Margin | -2.50% | 2.72% | 4.03% | -2.34% | -5.12% | 18.60% | Upgrade
|
| Free Cash Flow Per Share | -0.03 | 0.03 | 0.05 | -0.04 | -0.08 | 0.29 | Upgrade
|
| Cash Income Tax Paid | - | -36.96 | -19.73 | -88.14 | 9.28 | 1.46 | Upgrade
|
| Levered Free Cash Flow | -116.22 | 237.44 | 202.78 | 77.39 | 401.47 | 723.85 | Upgrade
|
| Unlevered Free Cash Flow | -99.71 | 255.44 | 226.38 | 100.23 | 415.15 | 730.96 | Upgrade
|
| Change in Working Capital | -265.66 | -265.66 | -67.52 | -377.46 | -350.16 | -142.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.